Skip to main content

LCD L36912: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)

LCD L36912, MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™), is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2021-11-25 and first in force 2017-03-06. The policy text runs 37 words, and its billing and coding article A56870 lists 2 ICD-10-CM codes that support medical necessity for 1 procedure code. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 2 covered ICD-10-CM codes: the same total as L36941 (Noridian Healthcare Solutions, LLC, 2 codes, revised 2026-02-05) and the same total as L36951 (CGS Administrators, LLC, 2 codes, revised 2025-09-04).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2021-11-25
Original effective
2017-03-06
Policy text
37 words
Covered ICD-10 codes (articles)
2

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L36912
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A56870: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56870 (Billing and Coding: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

A56870: Billing and Coding: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) (Billing and Coding, effective 2021-11-25)

Covered ICD-10-CM codes
2
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 2 covered ICD-10-CM codes in A56870
ICD-10-CMDescription (FY2027)
D05.11Intraductal carcinoma in situ of right breast
D05.12Intraductal carcinoma in situ of left breast

Procedure codes: 0045U.

Coverage indications, limitations and medical necessity

This contractor will provide limited coverage for the Oncotype DX ® DCIS assay (Genomic Health, Inc., Redwood City, CA) for women diagnosed with DCIS who are planning on having breast conserving surgery and considering adjuvant radiation therapy.

Summary of evidence (opening)

Ductal carcinoma in situ (DCIS) is a heterogeneous group of neoplastic lesions confined to the breast ducts and lobules. It is one of the most commonly diagnosed breast conditions, accounting for approximately 20% of newly diagnosed breast cancers in the United States. 1 Women diagnosed with DCIS are at risk for local recurrence, which may be either DCIS or progression to invasive breast carcinoma. The management of patients with DCIS is an area of controversy and historically treatment has included both surgical excision and radiation therapy. 2 Following surgical excision alone, local recurrences occur in approximately 25% to 30% of women by 10 years. 3 The addition of radiation therapy has been reported to reduce local recurrence risk by approximately 50% but has not been demonstrated to prolong overall or disease free-survival 3 . In an observational study of patients diagnosed with DCIS from 1988 to 2011, prevention of invasive in-breast recurrence with radiation therapy after lumpectomy did not improve 10-year breast cancer-specific mortality compared with lumpectomy alone. 4 Therefore, treating all women with radiation therapy following surgical excision may represent overtreatment for many, especially given that the majority of cases do not recur following surgery alone. Clinical and pathologic features do not reliably predict the risk of recurrence; therefore, validated biomarkers are needed that identify patients at low risk of local recurrence for whom less treatment is indicated and conversely distinguish patients at high risk of progression to invasive disease for whom more intensive treatment regimens are appropriate. Oncotype DX ® DCIS Score

Test Description

The DCIS Score is a ribonucleic acid (RNA) based assay measuring the expression of 5 proliferation genes, progesterone receptor (PR), GSTM1 and 5 reference genes (Figure 1) with results reported as a numerical score along with accompanying interpretive information. The assay is performed on formalin fixed paraffin-embedded (FFPE) tissue blocks containing DCIS. The DCIS Score was developed based upon analyses of multiple correlative science studies comparing gene expression profiles between invasive and DCIS tumor samples. 5 An algorithm was developed using scaling and category cut-points based on the analysis of the DCIS Score result in a separate cohort of DCIS patients. 6

Figure 1: Genes Comprising the DCIS Score.

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2017-03-06
Current revision effective
2021-11-25
Last reviewed by the contractor
2021-10-05
MCD version
30

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L36912 cover?

This contractor will provide limited coverage for the Oncotype DX ® DCIS assay (Genomic Health, Inc., Redwood City, CA) for women diagnosed with DCIS who are planning on having breast conserving surgery and considering adjuvant radiation therapy. The full 37-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L36912 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L36912?

The companion billing and coding article A56870 lists 2 ICD-10-CM codes in 1 group that support medical necessity; the first 2 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L36912?

A denial under LCD L36912 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56870's 2 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.